Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study

Mette Charlot; Lars Hougaard Nielsen; Jesper Lindhardsen; Ole Ahlehoff; Anne-Marie S Olsen; Morten Lock Hansen; Peter Riis Hansen; Jan Kyst Madsen; Lars Køber; Gunnar H Gislason; Christian Torp-Pedersen

doi:10.1093/eurheartj/ehs202

Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study

Mette Charlot, Lars Hougaard Nielsen, Jesper Lindhardsen, Ole Ahlehoff, Anne-Marie S Olsen, Morten Lock Hansen, Peter Riis Hansen, Jan Kyst Madsen, Lars Køber, Gunnar H Gislason, Christian Torp-Pedersen

Research output: Contribution to journal › Journal article › Research › peer-review

17 Citations (Scopus)

Abstract

The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated. We analysed the risk of adverse cardiovascular outcomes after discontinuation of 12 months of clopidogrel treatment.

Original language	English
Journal	European Heart Journal
Volume	33
Issue number	20
Pages (from-to)	2527-34
Number of pages	8
ISSN	0195-668X
DOIs	https://doi.org/10.1093/eurheartj/ehs202
Publication status	Published - 2012

Access to Document

10.1093/eurheartj/ehs202

Cite this

Clopidogrel discontinuation after myocardial infarction and risk of thrombosis : a nationwide cohort study. / Charlot, Mette; Nielsen, Lars Hougaard; Lindhardsen, Jesper; Ahlehoff, Ole; Olsen, Anne-Marie S; Hansen, Morten Lock; Hansen, Peter Riis; Madsen, Jan Kyst; Køber, Lars ; Gislason, Gunnar H ; Torp-Pedersen, Christian.

In: European Heart Journal, Vol. 33, No. 20, 2012, p. 2527-34.

Research output: Contribution to journal › Journal article › Research › peer-review

Charlot, Mette ; Nielsen, Lars Hougaard ; Lindhardsen, Jesper ; Ahlehoff, Ole ; Olsen, Anne-Marie S ; Hansen, Morten Lock ; Hansen, Peter Riis ; Madsen, Jan Kyst ; Køber, Lars ; Gislason, Gunnar H ; Torp-Pedersen, Christian. / Clopidogrel discontinuation after myocardial infarction and risk of thrombosis : a nationwide cohort study. In: European Heart Journal. 2012 ; Vol. 33, No. 20. pp. 2527-34.

@article{644e5630f4d34d2f96dc7b3a869e9745,

title = "Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study",

abstract = "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated. We analysed the risk of adverse cardiovascular outcomes after discontinuation of 12 months of clopidogrel treatment.",

author = "Mette Charlot and Nielsen, {Lars Hougaard} and Jesper Lindhardsen and Ole Ahlehoff and Olsen, {Anne-Marie S} and Hansen, {Morten Lock} and Hansen, {Peter Riis} and Madsen, {Jan Kyst} and Lars K{\o}ber and Gislason, {Gunnar H} and Christian Torp-Pedersen",

year = "2012",

doi = "10.1093/eurheartj/ehs202",

language = "English",

volume = "33",

pages = "2527--34",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "20",

}

TY - JOUR

T1 - Clopidogrel discontinuation after myocardial infarction and risk of thrombosis

T2 - a nationwide cohort study

AU - Charlot, Mette

AU - Nielsen, Lars Hougaard

AU - Lindhardsen, Jesper

AU - Ahlehoff, Ole

AU - Olsen, Anne-Marie S

AU - Hansen, Morten Lock

AU - Hansen, Peter Riis

AU - Madsen, Jan Kyst

AU - Køber, Lars

AU - Gislason, Gunnar H

AU - Torp-Pedersen, Christian

PY - 2012

Y1 - 2012

N2 - The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated. We analysed the risk of adverse cardiovascular outcomes after discontinuation of 12 months of clopidogrel treatment.

AB - The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated. We analysed the risk of adverse cardiovascular outcomes after discontinuation of 12 months of clopidogrel treatment.

U2 - 10.1093/eurheartj/ehs202

DO - 10.1093/eurheartj/ehs202

M3 - Journal article

C2 - 22798561

VL - 33

SP - 2527

EP - 2534

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 20

ER -